Luitpold Recalls Additional Hydralazine Injection Lots
This article was originally published in The Pink Sheet Daily
Executive Summary
Daiichi Sankyo subsidiary says it is investigating problem of possible particulate contamination.
You may also be interested in...
Daiichi Sankyo Gains Marketing Rights To Ajinomoto's Diabetes Drug
Phase I compound AJD101 has a new mechanism of action that stimulates insulin independent glucose uptake in preclinical studies, according to the two Tokyo-based drug makers.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.